Sugi Predict

Sugi Predict / Compounds / SCHEMBL4018739

SCHEMBL4018739

SCHEMBL4018739

CCCCC(CC)CNS(=O)(=O)c1ccc(CN(Cc2ccncc2)C(=O)C(=O)O)s1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ HTT P42858 6/20 0.35
▸ LMNA P02545 6/20 0.35
▸ SMN1; SMN2 Q16637 5/20 0.35
▸ GALR3 O60755 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ TSHR P16473 4/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ GLA P06280 1/20 0.35
▸ CYP2C9 P11712 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CHRM2 P08172 1/20 0.35
▸ CHRM4 P08173 1/20 0.35
▸ CHRM5 P08912 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ CHRM3 P20309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021417 0.84 LIMK2 (0.39) ALDH1A1NPSR1HTTLMNASMN1; SMN2
SCHEMBL4713480 0.83 HTT (0.44) ALDH1A1NPSR1HTTLMNASMN1; SMN2
SCHEMBL4022922 0.82 EPHX1 (0.39) ALDH1A1NPSR1HTTLMNASMN1; SMN2
SCHEMBL4713479 0.76 HTT (0.36) ALDH1A1NPSR1HTTLMNASMN1; SMN2
SCHEMBL1856431 0.76 SMN1; SMN2 (0.50) ALDH1A1HTTLMNASMN1; SMN2TSHR
SCHEMBL4711947 0.76 TSHR (0.41) ALDH1A1NPSR1HTTLMNASMN1; SMN2
SCHEMBL4019018 0.74 TDP1 (0.46) ALDH1A1HTTLMNASMN1; SMN2TSHR
SCHEMBL1853475 0.74 MEN1 (0.47) ALDH1A1HTTSMN1; SMN2TSHRKMT2A
SCHEMBL1853297 0.73 SMN1; SMN2 (0.45) HTTSMN1; SMN2TSHRKMT2AMEN1
SCHEMBL1855640 0.73 SMN1; SMN2 (0.47) ALDH1A1HTTLMNASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 — — US claimed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 — — US disclosed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 — — US disclosed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 — — US disclosed
EP-1986637-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS Laboratoires Serono SA (CH) 2008-11-05 — — EP disclosed
WO-2007093557-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS LABORATOIRES SERONO S.A. (CH) 2007-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections STS, TST, SULT1A1 ALDH1A1 692/4885NPSR1 1526/4885HTT 4318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.